The prevalence of diabetic kidney disease among US adults with diabetes has remained steady at ∼25% over the last 20 years despite increased use of glucose-lowering medications and renin-angiotensin-aldosterone system (RAAS) inhibitors.1 The presence of kidney disease is the main driver of the increased mortality observed in the type 2 diabetes mellitus (T2DM) population.2 Thus, despite some evidence that intensified glycemic control and RAAS blockade mitigate aspects of diabetic microvascular sequelae, including progression of kidney disease,3,4 patients with T2DM and comorbid kidney disease still have an elevated risk for death and cardiorenal complications.